Skip to content

Psychiatric and legal considerations for ketamine treatment within prison settings.

Michael Bayrhammer-Savel, Martin Ortner, Marie-Claire Van Hout, Arkadiusz Komorowski

Frontiers in psychiatry January 1, 2024 DOI: 10.3389/fpsyt.2024.1316108 via PubMed

Summary

AI-generated from the abstract

People in prison have a fundamental right to health care that matches community standards, which includes access to effective medications for mental health conditions. Standard antidepressants often fail for those with depression and high suicide risk, a common problem in prisons. This article argues that denying effective treatment, such as ketamine therapy, may violate human rights under international law and UN standards. The authors discuss the psychiatric and legal arguments for and against using ketamine in prisons, noting potential benefits for severe depression and suicidality but also risks like unknown long-term effects and abuse. They conclude that more research is urgently needed given the lack of data on ketamine's use in prison populations.

Study at a glance

Characteristics Perspective or opinion paper Peer reviewed
Intervention Ketamine treatment
Topics Depression Ketamine
Keywords Human rights Suicidality Treatment resistant depression Prison mental health
Citations 6
Key finding Denying access to ketamine treatment in prisons may violate human rights, but more research is needed to understand its benefits and risks in this population.

Abstract

The fundamental right to equivalence of health care in prison settings encompasses the provision of medication to address mental health conditions. Considering the increased risk for self-harm among individuals dealing with depression, the limited effectiveness of conservative antidepressants is a major challenge in psychiatry. The high prevalence of suicidal tendencies within prison populations underscores the imperative for state-of-the-art pharmacological treatment to uphold adequate health care standards. Notably, the denial of access to effective medication could be deemed a violation of human rights of people living in prison according to international treaties, domestic law, and United Nations normative standards of detention. This article presents the authors' perspective on the accessibility of ketamine treatment in prison settings, discussing psychiatric and legal considerations as well as current challenges in this context. Implementing novel psychopharmacological interventions may alleviate the distress experienced by individuals struggling with depressive symptoms and suicidality. At the same time, unprecedented treatment alternatives bring along potential issues, including limited understanding of long-term effects and the risk of abuse. Given the scarce data-availability, a pressing need exists for further research on the benefits and risks of ketamine treatment within prison populations.

Explore topics

Comments

No comments yet.

Log in to comment